August 10, 2011

International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment

IRVINE, California and AMSTERDAM, August 10, 2011 /PRNewswire/ --

Agendia, a commercial-stage molecular cancer diagnostics company, today
announced that the 12th St. Gallen International Breast Cancer Conference
(2011) Expert Panel's recommendations highlight the value of molecular
subtyping - classifying patients by the particular biological subtype of
their tumor - in guiding treatment decisions for breast cancer patients.
According to the panel, "it is no longer tenable to consider breast cancer
as a single disease" and clinicians "should consider cases within the
various distinct subtypes in order to properly assess the relevant evidence
and arrive at appropriate therapeutic advice." The panel's updated
guidelines, which are released on a semiannual basis, appear in the August
2011 issue of Annals of Oncology in an article titled "Expert Consensus on
the Primary Therapy of Early Breast Cancer 2011" by Goldhirsch, et al
(Annals of Oncology 22: 1736-1747, 2011).

The panel's recommendations support the clinical value of Agendia's
BluePrint assay, which, in combination with the company's FDA-cleared
MammaPrint(R) recurrence test, can accurately classify all patients as
Basal, Luminal-A, Luminal-B, or ERBB2 (HER2) and help determine appropriate
treatment. Both clinically available, MammaPrint and BluePrint are two
components of Agendia's Symphony(TM) suite of breast cancer treatment
products, a comprehensive collection of genetic assays that help address
complex treatment decisions for any type and stage of breast cancer.

The panel also recognized that MammaPrint provided such accurate
prognoses that patients and physicians may decide that chemotherapy is not
required. MammaPrint identifies patients' risk of metastasis, placing them
into one of just two groups, high risk and low risk. Women in the low risk
group are able to be treated effectively and safely without undergoing
chemotherapy and its side effects.

"These recommendations reinforce what Agendia has known for some time -
that molecular subtyping is an invaluable component of the treatment
decision process in breast cancer," said Dr. Bernhard Sixt, CEO and
Cofounder of Agendia. "Along with MammaPrint's proven prognostic ability to
classify breast cancer patients according to recurrence risk, BluePrint and
Symphony's other tests offer a very powerful set of tools to help physicians
eliminate uncertainty and make better treatment decisions."

About Agendia:

Agendia [ ] is a leading global commercial
molecular diagnostic company that develops and markets genomic-based
diagnostic products that improve the quality of life for cancer patients and
simplifies complex treatment decisions for their physicians. Agendia's
Symphony(TM) suite of breast cancer products is based on the analysis of
hundreds of genes in a patient's breast and provides unprecedented
biological insight to address complex treatment decisions. Symphony(TM)
includes MammaPrint(R), the first and only FDA-cleared IVDMIA breast cancer
recurrence assay, as well as BluePrint(R), a molecular subtyping assay,
TargetPrint(R), an ER/PR/HER2 expression assay, and TheraPrint(R), a therapy
selection assay. Together, these tests help physicians determine a patient's
individual risk for metastasis, which patients will benefit from chemo or
hormonal therapy, and which patients do not require these treatments and can
instead be treated with other less arduous and costly methods.

In addition to the Symphony(TM) suite of tests, Agendia has a rich
pipeline of genomic products in development based on its world-class genomic
platform. The company also collaborates with pharmaceutical companies to
develop companion diagnostic tests in the area of oncology and is a critical
partner in the ISPY-2 and MINDACT trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer
Institute and is based in Irvine, California, United States, and Amsterdam,
the Netherlands. For more information, please visit

SOURCE Agendia B.V.